Impact of losartan and angiotensin II on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat vascular smooth muscle cells

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1587-1594

  Guo, Yan Song ^a   Wu, Zong Gui ^b   Yang, Jun Ke ^c   Chen, Xin Jing ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Angiotensin II; Losartan; Matrix metalloproteinase 9; Tissue inhibitor of metalloproteinase 1; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; GELATINASE B; LOSARTAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MESSENGER RNA;

ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE EXPRESSION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

RATTUS;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; GENE EXPRESSION REGULATION; LOSARTAN; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84916631715     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2952     Document Type: Article

References (26)

1. Peeters W, Moll FL, Vink A, et al: Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J 32: 2314-2325, 2011.
2. Siasos G, Tousoulis D, Kioufis S, et al: Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem 12: 1132-1148, 2012.
3. Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85: 1-31, 2005.
4. Yu YM and Lin HC: Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr Metab Cardiovasc Dis 20: 125-132, 2010.
5. Johnson JL, Dwivedi A and Somerville M: Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol 31: e35-e44, 2011.
6. An J, Nakajima T, Kuba K and Kimura A: Losartan inhibits LPS-induced inflammatory signaling through a PPAR-dependent mechanism in human THP-1 macrophages. Hypertens Res 33: 831-835, 2010.
7. Díez J: Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. Clin Ther 28: 832-848, 2006.
8. Hernandez-Trujillo Y1, Rodriguez-Esparragon F, Macias-Reyes A, Caballero-Hidalgo A, Rodriguez-Perez JC: Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. Cardiovasc Diabetol 7: 3, 2008.
9. Xu YM, Deepak S, Li GP and Zhao YN: Effect of angiotensin II type 1 receptor antagonist, losartan on inflammatory factor in atherosclerotic rabbits. Res Cardiocvasc Med 1: 127-131, 2013.
10. Xu HX, Li JJ, Li GS, et al: Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Acta Cardiol 62: 607-613, 2007.
11. Luan Z, Chase AJ and Newby AC: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23: 769-775, 2003.
12. Madala SK, Pesce JT, Ramalingam TR et al: Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 184: 3955-3963, 2010.
13. Yang DC, Ma ST and Tan Y: Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 116: 133-141, 2010.
14. Dabek J, Glogowska-Ligus J and Szadorska B: Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients. J Postgrad Med 59: 115-120, 2013.
15. Ding SF, Liu HJ, Lu Q, et al: Changes of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 during left ventricular remodeling in acute myocardial infarction patients after percutaneous coronary intervention. Biomed Res-India 24: 179-184, 2013.
16. Virdis A, Duranti E and Taddei S: Oxidative stress and vascular damage n hypertension: Role of angiotensin II. Int J Hypertens 2011: Epub, 2011.
17. Lee BS, Choi JY, Kim JY et al: Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein e(-/-) mice. Korean Circ J 42: 543-550, 2012.
18. Kaynar K, Ulusoy S, Ovali E, et al: TGF-beta and TNF-alpha producing effects of losartan and amlodipine on human mononuclear cell culture. Nephrology (Carlton) 10: 478-482, 2005.
19. Yaghooti H, Firoozrai M, Fallah S and Khorramizadeh MR: Angiotensin II differentially induces matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 production and disturbs MMP/TIMP balance. Avicenna J Med Biotechnol 2: 79-85, 2010.
20. Gu J, Liu X, Wang QX, et al: Angiotensin II increases CTGF expression via MAPKs/TGF-1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res 318: 2105-2015, 2012.
21. O'Reilly MA: Angiotensin II: tapping the cell cycle machinery to kill endothelial cells. Am J Physiol Lung Cell Mol Physiol 303: L575-L576, 2012.
22. deBlois D, Tea BS, Than VD, Tremblay J and Hamet P: Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 29: 340-349, 1997.
23. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO: Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278: 28-45, 2011.
24. Morand-Contant M, Anand-Srivastava MB and Couture R: Kinin B1 receptor upregulation by angiotensin II and endothelin-1 in rat vascular smooth muscle cells: receptors and mechanisms. Am J Physiol Heart Circ Physiol 299: H1625-H1632, 2010.
25. Pan P, Fu H, Zhang L, et al: Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol 11: 36, 2010.
26. Kranzhoeter R and Larsen D. Angiotensin II induces relaease of matrix metalloproteinases from human vascular smooth muscle cells via NF-kappa B. circulation 102:11-12, 2000.